Blog

Nelson Advisors Partner Lloyd Price has been invited to Chair the Health Data and Cyber Security panel at Health Tech Forward 2025 in Barcelona. &nbsp;&nbsp; Health Data Under Attack: Emerging Vulnerabilities in Healthcare The healthcare sector faces a rapidly escalating threat landscape, with data breaches and cyberattacks becoming more frequent, sophisticated, and impactful. The vulnerabilities are often a combination of persistent issues and newly emerging threats.. Some of the key themes expected to be discussed on the panel include: &nbsp;&nbsp; 1. Ransomware and Extortion Attacks &nbsp;&nbsp; Ransomware remains the single most significant threat, often leading to service disruption and data theft. &nbsp;&nbsp; 2. Third-Party and Supply Chain Risk &nbsp;&nbsp; The reliance on an interconnected ecosystem of vendors, business associates, and technology partners has created a major security blind spot. &nbsp;&nbsp; 3. Exploitation of Network and Edge Devices &nbsp;&nbsp; Vulnerabilities in critical network infrastructure are being rapidly exploited by threat actors. &nbsp;&nbsp; 4. Human Factors and Phishing Innovation &nbsp;&nbsp; While not new, social engineering tactics continue to be the most common initial access vector, and they are becoming more advanced. &nbsp;&nbsp; 5. Internet of Medical Things (IoMT) and Legacy Systems &nbsp;&nbsp; The blend of old and new technology in clinical settings creates unique security challenges. &nbsp;&nbsp; 6. Geopolitical and Nation-State Threats &nbsp;&nbsp; Cyber adversaries linked to hostile nation-states are increasingly interested in the healthcare sector for espionage, revenue generation, and disruption. &nbsp;&nbsp; Health Tech Forward 2025 &nbsp;&nbsp; Conference Name: Health Tech Forward 2025 Location: Palau de Congressos de Barcelona in Barcelona, Spain. Dates: December 3-4, 2025. Focus: Europe's premier event for health tech innovation and investment, featuring keynote speeches, dynamic panel discussions, and targeted 1:1 networking opportunities. Panel Topic Context: The panel falls under the track/topic of cybersecurity, compliance, and collaboration(often referred to as the "3C's"), addressing the critical security challenges facing the healthcare sector as it adopts new technologies. &nbsp;&nbsp; The conference agenda often covers themes ranging from AI insights and clinical breakthroughs to consumer tech &amp; wellness. &nbsp;&nbsp; <a data-mce-href="https://healthtechforward.com" href="https://healthtechforward.com" title="https://healthtechforward.com" target="_blank" rel="noopener">https://healthtechforward.com</a>

Nelson Advisors invited to Chair the Health Data and Cyber Security panel at Health Tech Forward 2025 in Barcelona

Russian old wooden abacus made of black and white pebbles and beige frame on dark green background in the center top view

As of November 2025, the HealthTech M&amp;A market has stabilized following the recalibration of 2023–2024. While we are not seeing the "growth at all costs" valuations of 2021, multiples have recovered for high-quality assets. The primary theme for late 2025 is selectivity. Buyers (both strategic and Private Equity) are deploying capital aggressively but only for companies with proven unit economics, clear paths to profitability, or "must-have" AI infrastructure.1. Current Valuation Multiples (November 2025) The spread between "average" and "premium" assets has widened significantly. Companies with proprietary AI or strong recurring revenue (SaaS) command the highest premiums.Revenue Multiples (EV / LTM Revenue)Premium AI &amp; Data &gt; 6.0x – 8.0x+ &gt; Companies with proven proprietary algorithms (not just wrappers) or clean, actionable data sets (e.g., drug discovery, imaging AI).Value-Based Care Tech &gt; 5.5x – 7.0x &gt; Platforms enabling risk-bearing models (e.g., population health, remote monitoring).Telehealth (Hybrid) &gt; 5.0x – 7.0x &gt; Mature platforms with hybrid (virtual + in-person) capabilities. Pure-play telehealth sees lower multiples.General HealthTech &gt; 4.0x – 6.0x &gt; The "standard" range for growing digital health SaaS with average retention/margins.Unprofitable/Early Stage &gt; 3.0x – 4.0x &gt; Startups with high burn rates or unclear ROI are seeing significant valuation compressionCurrent market intelligence suggests the following HealthTech M&amp;A landscape for November 2025.EBITDA Multiples (EV / LTM EBITDA) Used for mature, profitable companies and tech-enabled services.Profitable HealthTech &gt; 10x – 14x &gt; Established software firms with &gt;20% EBITDA margins.Tech-Enabled Services &gt; 10x – 12x &gt; Service-heavy models (RCM, provider services) that scale slower than pure software.Broader Healthcare &gt; ~12.8x &gt; Median across the wider healthcare sector (hospitals, services, devices).2. The 4 Variables Driving Valuations Now If you are looking to understand why one company trades at 4x and another at 8x, it comes down to these four variables:A. The "AI Premium" (Reality vs. Hype)&nbsp;In 2025, buyers have moved past the hype phase. You don't get a premium just for saying "GenAI."Driver: Buyers are paying up for workflow integration. Does the AI actually reduce administrative burden or improve diagnostic accuracy today? Impact: Validated AI solutions in diagnostics, drug discovery, and RCM (Revenue Cycle Management) are seeing the highest multiples (often 8x+ revenue). B. Path to Profitability (Rule of 40) The "growth at all costs" era is definitively over.Driver: Private Equity (PE) firms—who are sitting on record "dry powder"—are prioritizing the "Rule of 40" (Growth % + Profit Margin % &gt; 40). Impact: Companies burning cash without a clear 12-18 month path to break-even are seeing offers with heavy structures (earn-outs) or significantly compressed multiples (3x revenue). C. The Value-Based Care (VBC) "Enablers" Healthcare is still shifting from Fee-For-Service to Value-Based Care.Driver: Payers and large Health Systems are desperate for tech that helps them manage risk and patient populations outside the hospital walls. Impact: Tech that proves it can lower cost of care (e.g., Remote Patient Monitoring, Chronic Disease Management) commands a premium because it directly impacts the buyer's bottom line. D. Regulatory &amp; Political Clarity Driver: With the 2024 US election cycle in the rearview, regulatory pathways for digital health (particularly AI and reimbursement codes) have stabilised.Impact: This reduced uncertainty has encouraged large strategic buyers (Pharma, MedTech) to resume "mega-mergers" and consolidation plays. 3. Notable HealthTech Deal Activity (2025 Examples) The market has seen a resurgence of "Platform" deals—large strategic acquisitions designed to build dominant positions in specific verticals.Johnson &amp; Johnson acquires Intra-Cellular Therapies ($14.6B): Bio-Pharma Tech. Highlights the massive premium paid for late-stage, de-risked assets in the central nervous system space.Clearlake Capital acquires ModMedicine ($5.3B): Practice Management SaaS. A classic PE play for a mature, profitable "system of record" widely used by specialty practices. Stryker acquires Inari Medical ($4.9B): MedTech. Demonstrates the continued appetite for medical devices that offer minimally invasive solutions with clear reimbursement pathways. Optum acquires Amedisys ($3.9B): Home Health / Tech-Enabled Services. (Note: Heavily scrutinised by regulators). Signals the continued push by payers to own the "home" setting of care. Roper Technologies acquires CentralReach ($1.9B): Behavioral Health SaaS. Highlights the strong demand for vertical-specific software, specifically in the autism/behavioral health space. 4. Sub-Sector Snapshot Provider Tech (RCM &amp; IT): Stable. Hospitals are squeezed financially, so they are buying tech that automates back-office tasks (RCM) to save money. High volume of deals, moderate multiples.Life Sciences IT (Drug Discovery): Bullish. Pharma giants facing patent cliffs are aggressively buying AI-driven drug discovery platforms to speed up R&amp;D.Digital Health (Consumer/Telehealth): Bearish / Mixed. The "Direct-to-Consumer" model is struggling with high customer acquisition costs. Valuation multiples here remain depressed unless the company has pivoted to B2B (selling to employers/payers).To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

HealthTech M&A Multiples November 2025: Current Trends and Variables driving valuations

Hello November. Desk calendar for planning November 2025.

Key developments in the European MedTech sector for the week of November 21st 2025, have been dominated by major regulatory shifts regarding AI, significant capital injections, and activity surrounding two major industry conferences.1. Regulatory &amp; Policy: The "AI Act Pause" ProposalThe most significant strategic development this week is the European Commission's proposal to delay the enforcement of "high-risk" AI rules for medical devices. The News: As part of a new "Digital Omnibus" package introduced this week, the Commission has proposed a "targeted implementation delay" for the EU AI Act. Impact: This would effectively pause the enforcement of strict obligations for high-risk AI systems (which includes many AI-driven medical devices) that were set to apply from August 2026. Why it matters: MedTech industry groups have been lobbying for this, arguing that the "dual regulatory burden" of complying with both the Medical Device Regulation (MDR) and the new AI Act would stifle innovation. If passed, this gives manufacturers a critical breathing room of up to 16 months to align their technical standards. 2. Investment &amp; FundingA €650M Boost Despite a generally difficult fundraising climate, this week saw a massive commitment to the European life sciences ecosystem.Sofinnova Partners closes Capital XI: The Paris-based venture capital firm announced the final close of its "Capital XI" fund at €650 million ($750M). Focus: The fund is specifically targeted at early-stage biotech and MedTech companies. This is a strong signal of investor confidence in European deep-tech and medical innovation, providing much-needed liquidity for startups facing the "series A crunch." 3. Major Events: Medica &amp; Helsinki Summit Europe hosted two pivotal industry gatherings this week, driving networking and partnership announcements. MEDICA 2025 (Düsseldorf, Nov 17–20): One of the world's largest medical trade fairs concluded yesterday. Key themes this year included "Hospital 4.0," sustainable manufacturing, and the integration of generative AI into clinical workflows. MedTech Innovation Helsinki Summit (Nov 19): This high-profile summit focused on bridging the gap between Nordic innovation and global capital. Highlight: The event featured a pitch competition with a €300,000 investment prize, hosted in partnership with Global Medical Solutions and Samsung Medical. The event underscored the growing role of corporate venture capital (CVC) in the European market. 4. Product &amp; Corporate Moves Zydus Lifesciences (CE Mark): While announced just prior to this week, the industry is currently digesting the impact of Zydus' subsidiary, Amplitude Surgical, receiving the CE Mark for its "Andy" robotic surgical system. This clears the way for a new competitor in the European orthopaedic robotics market, challenging established US players. Global M&amp;A Ripples: The sector is also reacting to Abbott’s massive $21 billion acquisition of Exact Sciences(announced earlier but dominating discussion at Medica). For European MedTech, this consolidation signals likely intensified competition in the non-invasive cancer diagnostics space across the continent. &nbsp; &gt;&gt;&gt;&nbsp; &nbsp; European HealthTech (digital health, data and AI) developments for the week of November 17–21, 2025 are detailed below. While the broader medical device sector is focused on hardware delays, the HealthTech conversation this week shifted sharply toward data access and AI liability. 1. Regulation &amp; Policy: A Double-Edged Sword for AIThe biggest structural shift for European HealthTech occurred on Wednesday, November 19, with the European Commission's "Digital Omnibus" proposal. The "Data Unlock" (GDPR Reform): Beyond the AI Act delay, the most critical update for HealthTech is a proposed change to GDPR. The Commission wants to classify "training AI models" as a "legitimate interest." Why this matters: Currently, HealthTech startups often struggle to use patient data to train algorithms without explicit, granular consent. If passed, this amendment could significantly lower the legal barrier for accessing real-world data (RWD) to build predictive models. The Counterpoint (WHO Warning): coinciding with this deregulation push, the World Health Organization (Europe) released a report this week warning of a "regulatory vacuum" regarding AI liability. They cautioned that while tools are being adopted rapidly, it remains unclear who is legally responsible, the software provider or the clinician, when an AI diagnostic tool makes an error. 2. Investment: FemTech &amp; UK Life SciencesWhile mega-rounds were quieter this week compared to earlier in the month (e.g., Qida’s €37M raise was Nov 4), specialized sectors saw fresh activity. Emm (UK) raises €7.7M: Bristol-based FemTech startup Emm secured €7.7M ($9M) in Seed funding on November 19. The Tech: They are developing a "smart menstrual cup" that uses biosensors to monitor health metrics remotely. This highlights a growing trend of "invisible" wearables that passively collect clinical-grade data. UK Government &amp; Sofinnova: As part of a broader life sciences package announced Nov 18, the British Business Bank committed €30 million specifically to Sofinnova’s new fund. This capital is earmarked for high-growth digital and biotech ventures, reinforcing the UK's post-Brexit push to remain a top hub for health innovation. 3. Innovation Highlight: AI in Practice (Ireland) The AI Awards Ireland (Nov 18) provided a look at which HealthTech solutions are gaining traction on the ground right now: Best AI in a Startup: Won by WHYZE Health, a platform that uses AI to match patients with clinical trials using real-world evidence. This addresses a major bottleneck in European pharma: slow patient recruitment. Clinical Efficiency: St. Luke’s Radiation Oncology Network won for an AI tool that automates "contouring" (outlining tumours) for radiation therapy. The system reportedly reduces manual planning time by 50%, a concrete example of AI relieving workforce burnout. 4. Ecosystem &amp; Events European Digital Health Literacy Conference (Aalborg, Nov 17-18): This inaugural conference focused on the "human side" of HealthTech adoption. A key takeaway was the "digital divide", new EU data suggests that while apps are proliferating, elderly adoption remains stalled due to poor UX design, prompting calls for new "age-inclusive" software standards. Danish Tech in Silicon Valley: A delegation of Danish HealthTech startups is currently in Palo Alto (Nov 17-21) for the "Plug and Play" summit, actively seeking US commercial partners to scale European digital solutions transatlantic.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a> &nbsp;

This Week in European HealthTech and MedTech: 21st November 2025

Nelson Advisors have been invited to Chair the 'Finance in Healthcare: Pathways from VC to PE through M&amp;A Event' for the Healthcare Club at the IESE Business School, Barcelona in December 2025.<a data-mce-href="https://groups.iese.edu/healthcare/rsvp_boot?id=300117522" href="https://groups.iese.edu/healthcare/rsvp_boot?id=300117522" title="https://groups.iese.edu/healthcare/rsvp_boot?id=300117522" target="_blank" rel="noopener">https://groups.iese.edu/healthcare/rsvp_boot?id=300117522</a> The Founding Partners of Nelson Advisors believe strongly in sharing their experiences and knowledge of the HealthTech and MedTech markets with students across a wide range of UK and European Universities ranging from Oxford University and University of Cambridge to London Business School and University College London Global Business Schood for Health to IESE Business School. &nbsp;&nbsp; IESE Business School &nbsp;&nbsp; IESE Business School is the graduate business school of the University of Navarra, with its main campus located in Barcelona, Spain. It is consistently ranked among the top business schools globally, particularly for its MBA and Executive Education programs. &nbsp;&nbsp; Key Characteristics &nbsp;&nbsp; Global Mindset: IESE has a strong international focus with a highly diverse student body and campuses in Barcelona, Madrid, New York, Munich, and São Paulo.Case Method: The school is well-known for its extensive use of the case method, a teaching approach that uses real-world business problems to develop students' critical thinking, problem-solving, and decision-making skills.Values-Based Leadership: IESE emphasises a people centred vision and a commitment to ethics and social responsibility, aiming to educate leaders who can have a positive impact on business and society. &nbsp;&nbsp; Programmes &nbsp;&nbsp; IESE offers a variety of programs, including: &nbsp;&nbsp; Full-time MBA: A 15- or 19-month program known for its global approach. The curriculum includes core courses in the first year and a wide selection of electives in the second.&nbsp;Executive MBA (EMBA): A part-time program designed for experienced professionals.Global Executive MBA (GEMBA): A blended program with on-campus and online components.Executive Education Programs: These are consistently ranked among the best in the world and are aimed at functional managers, senior executives, and C-suite leaders. &nbsp;&nbsp; Rankings and Reputation &nbsp;&nbsp; IESE's programs are highly regarded in international rankings. Recent rankings include: &nbsp;&nbsp; Financial Times Global MBA Ranking: Consistently ranked in the top 10, with a #3 ranking in 2025.The Economist Full-time MBA Ranking: Ranked #1 in the world in 2021.Financial Times Executive Education: Ranked #1 for six consecutive years (2015-2020) and continues to be highly ranked.The school holds triple accreditation from AACSB, AMBA, and EQUIS. &nbsp;&nbsp; IESE Business School &gt; Healthcare Club &nbsp;&nbsp; The IESE Business School Healthcare Club is a professional student club at IESE that focuses on the healthcare industry. Its mission is to support IESE students who are interested in pursuing a career in healthcare by providing them with the resources, knowledge, and networking opportunities they need. &nbsp;&nbsp; The club's activities are designed to help students: &nbsp;&nbsp; Learn about the healthcare sector: They organize seminars, workshops, and panels with industry experts, IESE professors, and alumni. These events cover various aspects of the healthcare industry, from pharmaceuticals and medical devices to digital health and healthcare consulting.Network with industry professionals: The club facilitates connections with leading healthcare companies, startups, and alumni. They host networking events, company visits, and an annual "Healthcare Day" conference, which brings together top professionals to discuss current trends and challenges in the industry.Find a job in the healthcare sector: The club offers career support through CV/cover letter workshops, interview preparation, and a mentorship program that connects students with experienced professionals. They also organize career treks to major healthcare hubs like Basel, Switzerland, and Madrid, Spain, where students can visit companies and network with potential employers.The IESE Healthcare Club plays a key role in positioning the IESE MBA as a source of top talent for healthcare companies and is a valuable resource for students aiming to transition into or advance their careers in this dynamic and impactful industry.

Nelson Advisors invited to Chair the panel at IESE Business School event - Finance in Healthcare: Pathways from VC to PE through M&A

Nelson Advisors Partner Lloyd Price has been invited to speak at the Leaders in Health Summit 2025 in London and debate the 'Business Case for Ultra Personalisation'&nbsp;Event Details &nbsp;&nbsp; Date: Tuesday, November 18, 2025 &nbsp;&nbsp; Location: Havas Kings Cross Building, London &nbsp;&nbsp; Host: WellFounded (Founders Health &amp; Concierge Performance Medicine) &nbsp;&nbsp; Access: By invitation/application only (free for invited guests/applicants) &nbsp;&nbsp; Source: https://wellfounded.health/summit-schedule &nbsp;&nbsp; Core Theme &nbsp;&nbsp; The overarching question driving the Summit is: "Can Precision Breakthroughs, Regulatory Revolution &amp; AI (Re)Humanise Healthcare?"The goal is to explore how to "Make medicine personable again."Key Areas of Focus (The Deeper Shift) &nbsp;&nbsp; The summit is dedicated to exploring the fundamental reimagining of medicine around the individual, moving beyond just diagnostics and treatment. The topics include: &nbsp;&nbsp; Direct-to-Customer Preventive Services: Exploring the business models and innovations in consumer health that are attracting significant investment and moving care away from traditional clinical settings.Concierge Practices &amp; Human-Centred Care: Discussing new models of healthcare delivery that promise deeply personalised, high-touch, human-centred care.Longevity Clinics: Examining the radically tailored pathways and scientific developments offered by longevity and healthspan clinics.AI Redefining Medicine: Analysing how Artificial Intelligence is fundamentally changing the way patients and clinicians interact with medicine.The Fifth 'P': Personable: Moving beyond Professor Leroy Hood's "4P's" (Proactive, Precise, Preventive, Personalised) to address the need to make healthcare truly Personable.Critical DebatesThe Summit will also delve into the complexities and challenges of this transformation, with provocations such as: &nbsp;&nbsp; Is AI an efficiency tool that buys the profession more time, or is it dissolving the essential clinician–patient bond?Are customised therapies, biotech breakthroughs, and loosely regulated trials truly testable and scalable for the wider population?The event is designed to bring a "human lens" to the future of healthcare, from hyper-targeted treatments to achieving human flourishing.&gt;&gt;To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk﻿</a>

Nelson Advisors invited to speak at the Leaders in Health Summit 2025 and debate the 'Business Case for Ultra Personalisation'

complex messy management, organization and innovation, chaotic decision tree, complicated business process

The process from pitching an idea ("Board") to its widespread use by clinicians and patients ("Ward") in HealthTech and MedTech is a multi-stage Health Technology Pathway focused on demonstrating value, ensuring safety, and securing buy-in. It is typically non-linear and requires constant engagement with diverse stakeholders.Here is an overview of the key phases:1. Idea Creation and Value Proposition (The Pitch) 💡 This initial phase establishes the foundation for the technology.Identify the Unmet Need: The process begins with identifying a clear problem or gap in clinical care that the proposed technology (device or digital solution) can solve. This must be a patient-centric need. Concept &amp; Development: The technology is designed with the end-user (clinicians and patients) in mind to ensure an intuitive and seamless experience that doesn't disrupt workflow. Value Proposition: A clear statement is developed to explain the benefits to the healthcare system, clinicians, and patients. This typically includes improvements in patient outcomes, cost-effectiveness, and/or operational efficiency. Early Engagement: Innovators engage early with key stakeholders, including regulators, commissioners, and patient groups, to align the technology's design and evidence requirements with the needs of the healthcare system.&nbsp;2. Regulatory Approval and Evidence Generation (The Validation) ✅ This is the critical phase where the technology is tested and formally approved for use.Clinical Trials/Testing: Rigorous studies are conducted to generate clinical evidence demonstrating the safety and effectiveness of the solution. This is essential for regulatory and adoption decisions. Regulatory Approval: The technology must meet stringent regulatory standards (e.g., FDA in the US, MHRA in the UK, MDR/IVDR in the EU) to be classified and marketed as a medical device or digital health solution. This often involves a risk-based approach, with higher-risk devices requiring more rigorous review. Health Technology Assessment (HTA): Independent bodies (like NICE in the UK) assess the clinical and cost-effectiveness of the technology compared to existing standard care. A positive HTA recommendation is often a prerequisite for national funding and commissioning. Post-Market Surveillance Planning: A plan is established for ongoing monitoring of the device's safety and performance once it's in use. 3. Funding, Commissioning, and Implementation (The Adoption) 🏥 Once the technology is proven safe and effective, the focus shifts to securing funding and integrating it into clinical practice.Funding and Procurement: The technology must secure a clear funding or reimbursement pathway. This involves navigating complex procurement routes and demonstrating the long-term value for money to health system commissioners. Commissioning and Local Planning: Healthcare organizations (e.g., Integrated Care Systems) decide to purchase and integrate the technology. This involves thorough mapping of existing clinical workflows to identify necessary process changes. Implementation &amp; Pilot Programs: A phased rollout is typically recommended, starting with pilot programs in specific departments or hospitals. This allows for real-world testing, gathering user feedback, and refining the implementation plan before a full-scale launch. Clinical Champion Buy-in: Identifying and empowering clinical champions—doctors, nurses, or other clinicians who are enthusiastic about the technology—is crucial. They drive local change, train peers, and provide essential feedback. 4. Clinician and Patient Adoption (The Ward) 🤝 The final stage ensures the technology is routinely and effectively used by its target users.Training and Support: Comprehensive, tailored training is provided to all end-users (clinicians, administrative staff, and patients). Ongoing, easily accessible support is vital to address issues as they arise. User-Centric Design: Technology adoption is significantly improved if the solution is intuitive and demonstrably saves the user time or significantly enhances patient care, rather than just adding to their workload. Continuous Feedback Loop: A mechanism for collecting and acting on feedback from frontline clinicians and patients must be established. This allows for iterative improvements to the product and the local implementation process. Measuring Outcomes: Organizations continuously monitor key performance indicators (KPIs) to ensure the technology delivers the promised benefits (e.g., reduced waiting lists, improved patient safety, better treatment outcomes). Cultural Change: Successful adoption requires overcoming system inertia and building a culture where innovation is valued and embedded into routine practice across the organization—the true "Board to Ward"culture.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Nelson Advisors invited to Chair the Health Data and Cybe...

HealthTech M&A Multiples November 2025: Current Trends an...

This Week in European HealthTech and MedTech: 21st Novemb...

Nelson Advisors invited to Chair the panel at IESE Busine...

Nelson Advisors invited to speak at the Leaders in Health...

Board to the Ward : Multi Stage HealthTech and MedTech P...